Impact Corelab, Inc. (ICI) announced the completion of work on its new corporate headquarters suite in Sacramento. In March, the company plans to move staff and operations into the facility, which adjoins the offices of Radiological Associates of Sacramento (RAS), whose radiologists provide specialized medical resources and support for customers of ICI’s imaging corelab services. The move is expected to enable a high degree of strategic collaboration between the two firms.
Located at 1500 Expo Parkway in Sacramento, the newly built office suite will allow ICI to concentrate its core activities in one location, including executive leadership, imaging operations, radiology read workstations, business development, data hosting/management, customer support and project management.
“We are pleased with the completion of our new headquarters space,” said Dr. Benjamin Franc M.D., M.S., acting CEO and Chairman of the Board. “This is an opportunity for us to consolidate the key corporate functions that will help fuel future growth as well as providing us with the proximity we wanted to enable close collaboration with our radiological affiliate, RAS, to serve the needs of ICI’s growing customer base.”
RAS’ team of 1,000 radiology professionals includes doctors, radiology specialists, and project managers to help support customers of ICI, which combines cloud-based data on demand technology with radiological services to deliver transparency, reliability, and query reduction for sponsors and CROs in image-based trials.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ifinatamab Deruxtecan Shows High Response Rates for Heavily Pretreated Small Cell Lung Cancer
September 9th 2024Potential first-in-class B7-H3 directed antibody drug conjugate ifinatamab deruxtecan shows potential to improve outcomes for patients living with difficult-to-treat form of lung cancer.